NSE filing, NSE: PGHL. Summary written from the filing by ALFA Finder's alert engine.
Procter & Gamble Health Ltd: key numbers
- Share price
- ₹5,670.50
- Market cap
- ₹9,413 Cr
- Revenue (annual)
- ₹1,408 Cr
- Net profit (annual)
- ₹326.9 Cr
- P/E (TTM)
- 26.4×Sector 45.9×
- Promoter holding
- 51.82%+0.00% QoQ
- FII holding
- 6.43%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Procter & Gamble Health Ltd
All →Procter & Gamble Health Q2 FY27 Results: Net Profit ₹111.5 Cr, Up 26.0% YoY
Procter & Gamble Health Ltd reported revenue from operations of ₹382.5 Cr (+17.7% YoY) and net profit of ₹111.5 Cr (+26.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹111.5 Cr · +26.0% YoY
Procter & Gamble Health Board Meeting Date
Procter & Gamble Health Limited will hold a board meeting on November 2, 2026, to consider and approve the unaudited financial results for the quarter ending September 30, 2026.
Procter & Gamble Health Other Announcement
Procter & Gamble Health informed shareholders about an extended SEBI-mandated special window for re-lodging rejected physical share transfer requests until February 4, 2027.
Procter & Gamble Health Management Change
Procter & Gamble Health shareholders approved the re-appointment of Mr. S. Madhavan as an Independent Director for a five-year term starting November 15, 2026.
- Execution
- 5 years
Procter & Gamble Health Annual General Meeting
Procter & Gamble Health held its 59th Annual General Meeting on September 3, 2026, where shareholders discussed financial results and directorial appointments.
Procter & Gamble Health Business Update
Procter & Gamble Health Limited has filed its Business Responsibility & Sustainability Report for the financial year ended March 31, 2026.
Other results update announcements
All →Wonderla Holidays Results Update
Wonderla reports best-ever Q2 with 42% income growth to ₹126 Cr and 90% EBITDA growth. H1 income up 41% to ₹378 Cr driven by new Chennai park.
UPL Results Update
UPL's Q2 FY27 revenue was ₹11,860 Cr with EBITDA of ₹2,312 Cr. H1 operational PATMI rose 33% YoY on sustained margin expansion.
JTL Defence Results Update
JTL Defence reported H1 FY27 revenue of Rs.410 Cr, up 11.4x YoY, with EBITDA of Rs.47 Cr. Adjusted PAT of Rs.3 Cr was impacted by asset revaluation depreciation.
Mold-Tek Packaging Results Update
Mold-Tek reported Q2 FY27 net profit up 36% to Rs 21.06 Cr and H1 profit up 23% to Rs 46.67 Cr. Revenue and sales volumes also rose across both periods.
Epigral Results Update
Epigral reported Q2 FY27 PAT of ₹64 Cr, up 26% YoY, with revenue at ₹752 Cr. EBITDA margin was 18% despite elevated raw material costs.
Eureka Forbes Results Update
Eureka Forbes reported Q2 FY27 revenue of ₹889.6 Cr and PAT of ₹73.3 Cr, both up ~19% YoY. EBITDA margin hit a lifetime high of 13.6%.